Squawk on the Street

Cramer's Morning Take: Meta 8/1/24

Jim and Jeff discuss the earnings report from this mega cap tech stock. Become a CNBC Investing Club member to go behind the scenes with Jim Cramer and Jeff Marks as they talk candidly about the market’s biggest headlines. Signup here: cnbc.com/morningtake CNBC Investing Club Disclaimer

Duration:: 6m
Broadcast on:: 01 Aug 2024
Audio Format:: mp3

CNBC Investing Club Disclaimer

"I won't let my active psoriatic arthritis joint symptoms define me." Emerge as you! Tramphia, Guselcomab, is proven to significantly reduce joint pain, stiffness, and swelling in adults with active psoriatic arthritis. Some patients even reported less fatigue, as assessed by survey one week prior. Results may vary. Tramphia is taken by injection six times a year after two starter doses at week zero and four. Serious allergic reactions may occur. Tramphia may increase your risk of infections and lower your ability to fight them. Before treatment, your doctor should check you for infections and tuberculosis. Tell your doctor if you have an infection or symptoms of infection, including fever, sweats, chills, muscle aches, or cough. Tell your doctor if you had a vaccine or plan to. Emerge as you! Learn more about Tramphia, including important safety information at Tramphia.com or call 1-877-578-3527. See our ad in Food & Wine magazine. For patients prescribed Tramphia, cause support may be available. What's on the horizon for financial markets? At PJIM, it's a question that over 1,400 investment professionals relentlessly research in pursuit of your long-term goals. Specialized across asset classes but united in collaboration. Our teams provide global and local expertise. Our investments shape tomorrow, today. Pursue your tomorrow with PJIM, a leading global asset manager. Jim Kramer here to share with you a sample of my take on the market from today's CBC Investing Club Morning Meeting. I'm going to tell you, I have a kind of crazy feeling about today. And the reason I do is because we have the tenure under four. And that means that people are reacting to these company like a Wayfair that's not doing that well. Come to the McDonald's not doing that well. The overall sense that the discretionary category is doing very, very poorly. And I think that's what's controlling the tenure. And I don't want to see that. I think the fed didn't cut yesterday. No, they did not. They did signal cuts in September. Sounds like it is on the table. They're watching inflation data and the job data. And we'll get a jobs number tomorrow as well. But yeah, it's a good back too. We had a very big move yesterday, especially in the semiconductors. NVIDIA Broadcom both were a double digit percentage. So a big move there. And obviously, meta is the star of what's happening today. Without meta, it'd be a much different market. Yes, it would be. Now, meta, one of the things that's very exciting about it, it's the first time I have read about what's going to happen in the future. 25 is a roadmap. 25 and 26 kind of took off the table the idea of, well, what are we doing this? And the idea is, is that right now if you're an advertiser, you can go to them and they'll tell you where your ad should be. You'll argue and then they'll say, okay, I don't know. But right at this very moment, the advertisers are all recognizing that Mark has a better view of where the ad should be. Then you say, just say, listen, here's my copy. I want this insertable. Now, since next year, you'll just say, look, I want an ad. It'll be better done by them than you. Yeah, he's talking about advertisers just giving them their budget and they'll put it to work. You know, it's interesting. Last time they reported, the market was really concerned about their spending on AI. But this time they really explained how AI is driving better engagement, recommendations. It's improving the monetization efficiency. Now people are taking their cap expending and saying, no, they're generating a strong return on this. It's worth it. And that's a big difference. That's a big reason why you had such a big revenue number. Guidance was strong. Earnings were great and the stocks up almost 9% as a result. Yeah. And I think that you're coming with a holistic platform. You're staying on WhatsApp. You're staying on Instagram. You're on one thread. They called out young adults in the US are using Facebook. People have not been able to reach that cohort. He has, by the way, the Raybans. I know we joke, but my daughter wears the Raybans. They can take pictures everywhere. You can ask the Raybans thing. Really rather remarkable. So anyway, an impressive marks up the road. Join the CMC investing club with Jim Kramer to catch my member exclusive warning meetings every day at 10 20 a.m. Visit cmbc.com/morningtake to become a member today. That's one word. Morning take. All opinions expressed by Jim Kramer on this podcast and in connection with the CNBC investing club are solely Kramer's opinions and do not reflect the opinions of CNBC, NBC, NBC, Universal or their parent company or affiliates and may have been previously disseminated by Kramer on television, radio, internet or another medium. No specific outcome or profit is guaranteed in connection with your reliance upon or other use of the content from Kramer. The opinions offered in connection with this podcast and the CNBC investing club are not an attempt to induce any particular trading behavior, investment or strategy. You should be aware of the risk of loss in following any strategy or investment discussed in the content from Kramer. To view the full CNBC investing club disclaimer, please visit cmbc.com/investingclubdisclaimer. I won't let my active psoriatic arthritis joint symptoms define me. Emerge as you. Tremfia, Guselcomab, is proven to significantly reduce joint pain, stiffness and swelling in adults with active psoriatic arthritis. Some patients even reported less fatigue as assessed by survey one week prior. Results may vary. Tremfia is taken by injections six times a year after two starter doses at week zero and four. Serious allergic reactions may occur. Tremfia may increase your risk of infections and lower your ability to fight them. Before treatment, your doctor should check you for infections and tuberculosis. Tell your doctor if you have an infection or symptoms of infection including fever, sweats, chills, muscle aches or cough. Tell your doctor if you had a vaccine or plan to. Emerge as you. Learn more about Tremfia including important safety information at tremfia.com or call 1-877-578-3527. See our ad in Food & Wine magazine. For patients prescribed Tremfia, cost support may be available.